Spinraza: The criteria will be expanded in Quebec/Canada

to include patients who: are pre-symptomatic with two or three copies of SMN2 gene;


have had disease duration of less than six months, two copies of the SMN2 gene, and symptom onset after the first week after birth and on or before seven months of age; or

are under the age of 18 with symptom onset after six months of age and who have never achieved the ability to walk independently.

Patients will be required to undergo ongoing assessment to monitor for improvement over time and must meet renewal criteria for continuation of treatment.

Cure SMA Canada Facebook
CureSMA Canada News

Publicerat av


Teammember and representation during the time when the girls are busy. :) /Jan

2 reaktioner till “Spinraza: The criteria will be expanded in Quebec/Canada”

  1. 👏Congratulations Canada, you are doing it right. Do not rule out adults, as other countries do. It is ethically just right, everywhere in the countries where Spinraza is used for all, one celebrates progress and the victory over death.🙂

Kommentarer inaktiverade.